mRNA Vaccines Against COVID-19 as Trailblazers for Other Human Infectious Diseases DOI Creative Commons
Rossella Brandi, Alessia Paganelli, Raffaele D’Amelio

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(12), P. 1418 - 1418

Published: Dec. 16, 2024

mRNA vaccines represent a milestone in the history of vaccinology, because they are safe, very effective, quick and cost-effective to produce, easy adapt should antigen vary, able induce humoral cellular immunity. Methods: To date, only two COVID-19 one RSV have been approved. However, several currently under development for prevention human viral (influenza, immunodeficiency virus [HIV], Epstein–Barr virus, cytomegalovirus, Zika, respiratory syncytial metapneumovirus/parainfluenza 3, Chikungunya, Nipah, rabies, varicella zoster herpes simplex 1 2), bacterial (tuberculosis), parasitic (malaria) diseases. Results: RNA viruses, such as severe acute syndrome coronavirus (SARS-CoV)-2, HIV, influenza, characterized by high variability, thus creating need rapidly circulating strain, task that can easily accomplish; however, speed variability may be higher than time needed vaccine adapted. vaccines, using lipid nanoparticles delivery system, act adjuvants, powerfully stimulating innate well adaptive immunity, both humoral, which is waning, cell-mediated, highly persistent. Safety profiles were satisfactory, considering slight increase prognostically favorable anaphylactic reactions young females myopericarditis males has observed. Conclusions: The pandemic determined shift use RNA: after having used medicine micro-RNAs tumor new era anti-infectious begun, great development, either improve already available, but unsatisfactory, or develop protective against infectious agents no preventative tools realized yet.

Language: Английский

mRNA Vaccines Against COVID-19 as Trailblazers for Other Human Infectious Diseases DOI Creative Commons
Rossella Brandi, Alessia Paganelli, Raffaele D’Amelio

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(12), P. 1418 - 1418

Published: Dec. 16, 2024

mRNA vaccines represent a milestone in the history of vaccinology, because they are safe, very effective, quick and cost-effective to produce, easy adapt should antigen vary, able induce humoral cellular immunity. Methods: To date, only two COVID-19 one RSV have been approved. However, several currently under development for prevention human viral (influenza, immunodeficiency virus [HIV], Epstein–Barr virus, cytomegalovirus, Zika, respiratory syncytial metapneumovirus/parainfluenza 3, Chikungunya, Nipah, rabies, varicella zoster herpes simplex 1 2), bacterial (tuberculosis), parasitic (malaria) diseases. Results: RNA viruses, such as severe acute syndrome coronavirus (SARS-CoV)-2, HIV, influenza, characterized by high variability, thus creating need rapidly circulating strain, task that can easily accomplish; however, speed variability may be higher than time needed vaccine adapted. vaccines, using lipid nanoparticles delivery system, act adjuvants, powerfully stimulating innate well adaptive immunity, both humoral, which is waning, cell-mediated, highly persistent. Safety profiles were satisfactory, considering slight increase prognostically favorable anaphylactic reactions young females myopericarditis males has observed. Conclusions: The pandemic determined shift use RNA: after having used medicine micro-RNAs tumor new era anti-infectious begun, great development, either improve already available, but unsatisfactory, or develop protective against infectious agents no preventative tools realized yet.

Language: Английский

Citations

1